Sodiumglucose cotransporter 2 inhibitor as a new hypoglycemic drug is available in Chinese market. In addition to its hypoglycemic effect, it has effect of cardiovascular protection, such as diuresis and natriuresis, which can relieve heart load, improve myocardial energy metabolism and vascular endothelial function. In recent years, several largescale randomized controlled trials have also confirmed that such drugs can significantly reduce the risk of atherosclerotic events, heart failure hospitalization, cardiovascular and total mortality, and delay the progression of chronic kidney disease.